Neil T. Pfister

Neil T. Pfister

Auto-generated profile, based on publicly available information

Neil T. Pfister

Numenos, New York, New York, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2024 in medRxiv
Verified
Preprint
Open access
PDF file
URUdbhav S. Ram
Udbhav S. Ram
JPJoel A. Pogue
Joel A. Pogue
MSMichael Soike
Michael Soike
NPNeil T. Pfister
Neil T. Pfister
RJRojymon Jacob
Rojymon Jacob
CCCarlos E. Cardenas
Carlos E. Cardenas
Segmentation of abdominal organs in clinical oncological workflows is crucial for ensuring effective treatment planning and follow-up. However, manually generated segmentations are time-consuming and labor-intensive in addition to experiencing inter-observer variability. Many deep learning (DL) and Automated Machine Learning (AutoML) frameworks have emerged as a solution to this challenge and show promise in clinical workflows. This study presents a comprehensive evaluation of existing AutoML frameworks (Auto3DSeg, nnU-Net) against a state-of-the-art non-AutoML framework, the Shifted Window U-Net Transformer (SwinUNETR), each trained on the same 122 training images, taken from the Abdominal Multi-Organ Segmentation (AMOS) grand challenge. Frameworks were compared using Dice Similarity Coefficient (DSC), Surface DSC (sDSC) and 95th Percentile Hausdorff Distances (HD95) on an additional 72 holdout-validation images. The perceived clinical viability of 30 auto-contoured test cases were assessed by three physicians in a blinded evaluation. Comparisons show significantly better performance by AutoML methods. nnU-Net (average DSC: 0.924, average sDSC: 0.938, average HD95: 4.26, median Likert: 4.57), Auto3DSeg (average DSC: 0.902, average sDSC: 0.919, average HD95: 8.76, median Likert: 4.49), and SwinUNETR (average DSC: 0.837, average sDSC: 0.844, average HD95: 13.93). AutoML frameworks were quantitatively preferred (13/13 OARs p>0.0.5 in DSC and sDSC, 12/13 OARs p>0.05 in HD95, comparing Auto3DSeg to SwinUNETR, and all OARs p>0.05 in all metrics comparing SwinUNETR to nnU-Net). Qualitatively, nnU-Net was preferred over Auto3DSeg (p=0.0027). The findings suggest that AutoML frameworks offer a significant advantage in the segmentation of abdominal organs, and underscores the potential of AutoML methods to enhance the efficiency of oncological workflows.

21 August 2025 in AI in Precision Oncology
Verified
Journal Article
Closed access
AWAmit D. Weiss
Amit D. Weiss
VFVitalay Fomin
Vitalay Fomin
DFDi Feng
Di Feng
ZTZuojian Tang
Zuojian Tang
JCJames Cai
James Cai
NPNeil T. Pfister
Neil T. Pfister
Background: Clinical research is limited by the capability to define the most important combinations of clinical features and biomarkers that predict therapeutic benefit. Here, we introduce Clinical trials Uncovering Real Efficacy Artificial Intelligence (CURE AI), a novel deep learning framework designed to predict individual patient benefit from a new therapeutic intervention compared to a standard of care. Methods: CURE AI utilizes a large clinicogenomic foundation model to understand the complex relationships between the vast clinical and multiomic features in clinical trial data. To build CURE AI, we trained a proprietary foundation model based on a deep learning architecture and training schema using a large collection of clinical and multiomics datasets. Using CURE AI, we seek to understand the complex interplay between clinicogenomic information from clinical trial arms to predict the magnitude of therapeutic benefit on the individual patient level. Results: In this article, we fine-tuned the CURE AI foundation model on lung cancer data from the OAK non-small cell lung cancer clinical trial. We observed that the trial could have been significant for progression-free survival (PFS), with fewer than half of the patients enrolled using CURE AI to guide trial enrollment ( p = 0.60 to p < 0.05). The fine-tuned CURE AI (termed CURE Lung Cancer) demonstrated direct generalizability on a held-out independent clinical trial dataset, the POPLAR trial, by converting an insignificant PFS endpoint to significance while also including the majority of patients (88%; p = 0.21 to p < 0.05). Conclusion: In summary, we developed a causally aware clinicogenomic deep learning platform that can learn to predict individualized patient benefit of investigational therapy compared to an existing standard of care. Because we use a foundation model trained on readily measurable patient characteristics, CURE AI can be applied to a variety of scientific and clinical uses, including adaptive clinical trials, toxicity prediction, treatment response prediction, and understanding of drug resistance and response mechanisms.